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Amyloid imaging studies of presymptomatic familial Alzheimer’s disease have revealed the striatum and thalamus to be the
earliest sites of amyloid deposition. This study aimed to investigate whether there are associated volume and diffusivity changes
in these subcortical structures during the presymptomatic and symptomatic stages of familial Alzheimer’s disease. As the
thalamus and striatum are involved in neural networks subserving complex cognitive and behavioural functions, we also
examined the diffusion characteristics in connecting white matter tracts. A cohort of 20 presenilin 1 mutation carriers underwent
volumetric and diffusion tensor magnetic resonance imaging, neuropsychological and clinical assessments; 10 were symptom-
atic, 10 were presymptomatic and on average 5.6 years younger than their expected age at onset; 20 healthy control subjects
were also studied. We conducted region of interest analyses of volume and diffusivity changes in the thalamus, caudate,
putamen and hippocampus and examined diffusion behaviour in the white matter tracts of interest (fornix, cingulum and
corpus callosum). Voxel-based morphometry and tract-based spatial statistics were also used to provide unbiased whole-brain
analyses of group differences in volume and diffusion indices, respectively. We found that reduced volumes of the left thalamus
and bilateral caudate were evident at a presymptomatic stage, together with increased fractional anisotropy of bilateral thalamus
and left caudate. Although no significant hippocampal volume loss was evident presymptomatically, reduced mean diffusivity
was observed in the right hippocampus and reduced mean and axial diffusivity in the right cingulum. In contrast, symptomatic
mutation carriers showed increased mean, axial and in particular radial diffusivity, with reduced fractional anisotropy, in all of
the white matter tracts of interest. The symptomatic group also showed atrophy and increased mean diffusivity in all of the
subcortical grey matter regions of interest, with increased fractional anisotropy in bilateral putamen. We propose that axonal
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injury may be an early event in presymptomatic Alzheimer’s disease, causing an initial fall in axial and mean diffusivity, which
then increases with loss of axonal density. The selective degeneration of long-coursing white matter tracts, with relative
preservation of short interneurons, may account for the increase in fractional anisotropy that is seen in the thalamus and
caudate presymptomatically. It may be owing to their dense connectivity that imaging changes are seen first in the thalamus
and striatum, which then progress to involve other regions in a vulnerable neuronal network.
Keywords: familial Alzheimer’s disease; presenilin 1 (PSEN1, PS1); presymptomatic; diffusion tensor imaging; subcortical atrophy
Abbreviations: DTI = diffusion tensor imaging; PMC = presymptomatic mutation carrier; SMC = symptomatic mutation carrier;
TBSS = tract-based spatial statistics
Introduction
Alzheimer’s disease affects an estimated 24 million people worldwide
and, unless more effective treatments are developed, this figure is
predicted to double every two decades (Ferri et al., 2005). A small
minority of cases are caused by autosomal dominantly inherited mu-
tations in the presenilin 1 (PSEN1), presenilin 2 (PSEN2) or amyloid
precursor protein (APP) genes, or by APP duplications. Although
rare, these mutations show virtually complete penetrance and mu-
tation carriers therefore provide a unique opportunity to gain insights
into the earliest stages of the disease. A wealth of evidence now
indicates that the symptoms of Alzheimer’s disease are preceded
by a long period of gradual accrual of pathological change (Price
and Morris, 1999; Bateman et al., 2012). The disappointing results
of trials of putative disease-modifying therapies in established
Alzheimer’s disease have shifted attention towards starting treat-
ment earlier in the disease course. Familial Alzheimer’s disease mu-
tation carriers represent a cohort in whom treatment could be
initiated at a presymptomatic stage and a number of such trials are
currently being designed (Reiman et al., 2010; Bateman et al., 2011).
As the individuals participating in these trials will have little or no
cognitive impairment, there is a need to understand the trajectory
of biomarker changes in presymptomatic familial Alzheimer’s
disease, in order to both assess disease progression and look for
therapeutic effects.
The cross-sectional results of the large international Dominantly
Inherited Alzheimer Network (DIAN) study have recently been
published, indicating that CSF biomarker changes are evident
over two decades before an individual’s expected age at symptom
onset, as determined by their parental age at onset (Bateman
et al., 2012). Reduced concentrations of CSF amyloid-b42 and
increased concentrations of CSF tau were detected at 25 and 15
years from expected symptom onset, respectively. Amyloid-b de-
position on Pittsburgh compound B-PET scans (Klunk et al., 2004)
and hippocampal volume loss were apparent at 15 years and cere-
bral hypometabolism at 10 years before expected symptom onset.
In the PSEN1 E280A Colombian kindred, altered hippocampal ac-
tivation on functional MRI during memory encoding has been
observed approximately two decades before expected age at
onset (Reiman et al., 2012). Presymptomatic hippocampal atrophy
has also been detected in longitudinal studies, which have fol-
lowed smaller cohorts through the presymptomatic stage to age
at symptom onset. At a group level, mutation carriers showed
hippocampal and whole brain volume loss compared with control
subjects at 3 and 1 year before symptom onset (Ridha et al.,
2006). However, longitudinal measures were able to detect
changes earlier, with differences in hippocampal and whole brain
atrophy rates observed at 5.5 and 3.5 years before symptom onset
in mutation carriers and cortical thinning at 4.1 and 1.8 years
presymptomatically for precuneus and posterior cingulate cortex,
respectively (Ridha et al., 2006; Knight et al., 2011a).
Previous volumetric imaging studies have mainly focused on the
neocortex and hippocampus, in view of the well recognized roles that
these structures play in higher cognitive functions and memory, and
their apparent vulnerability to Alzheimer’s disease pathology.
However, Pittsburgh compound B-PET studies have indicated that
prominent amyloid deposition first appears in the striatum and thal-
amus in presymptomatic familial Alzheimer’s disease (Klunk et al.,
2007; Knight et al., 2011b). These subcortical structures have
received relatively little attention from volumetric imaging studies
in Alzheimer’s disease. They are known to be significantly atrophied
in sporadic Alzheimer’s disease but it is not known how early this
atrophy occurs (de Jong et al., 2008). A recent familial Alzheimer’s
disease study reported decreased volumes of thalamus, caudate and
putamen in presymptomatic mutation carriers who were on average
15 years younger than their family’s median age at dementia diag-
nosis, with a trend towards increasing caudate size in those with
memory deficits who were 10 years younger (Lee et al., 2013).
Increased caudate volumes were reported in another cohort of pre-
symptomatic mutation carriers who were approximately a decade
younger than their expected age at symptom onset (Fortea et al.,
2010). This study also included diffusion imaging and found asso-
ciated changes in mean diffusivity in the caudate of presymptomatic
mutation carriers.
Although the thalamus and striatum are structures that are not
conventionally associated with Alzheimer’s disease, it has long
been known that they are affected by Alzheimer’s disease path-
ology (Braak and Braak, 1990, 1991). It is also becoming increas-
ingly recognized that, given their dense connections with the
cortex, they are involved in a variety of neural networks subser-
ving complex cognitive and behavioural functions (Middleton and
Strick, 2000). The caudate, for example, appears to play a key role
in supporting the planning and execution of behaviour needed to
achieve complex goals (Grahn et al., 2008), whilst thalamic nuclei
are involved in declarative memory function at a number of dif-
ferent levels (Van der Werf et al., 2003). There is a growing ap-
preciation of the idea that Alzheimer’s disease, and indeed
neurodegenerative diseases in general, should be considered as
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network disorders in which there is selective degeneration of vul-
nerable neuronal circuits (Warren et al., 2012). It therefore seems
appropriate to investigate the subcortical grey matter regions
involved in such networks, as well as the cortical areas and their
connecting white matter.
Diffusion tensor imaging (DTI) allows assessment of alterations
in tissue microstructure in specific brain regions and can be used to
examine the integrity of connecting white matter pathways
(Basser et al., 1994). DTI exploits the fact that water molecules
show preferential diffusion along the major axis of a white matter
fibre bundle (anisotropy), owing to barriers hindering perpendicu-
lar diffusion including axonal membranes and the myelin sheath.
The effects of a pathological process on white matter tracts can be
explored by investigating whether there are associated changes in
the overall magnitude of diffusion (mean diffusivity) or the degree
of its directionality (fractional anisotropy). Examining the compo-
nent eigenvalues of the diffusion tensor, from which fractional
anisotropy is derived, provides further information on how diffu-
sion is altered in both the principal direction of the tract (axial
diffusivity) and in the plane perpendicular to this (radial diffusiv-
ity). If there are changes in axial diffusivity and radial diffusivity
which are proportional, there will be no corresponding change in
fractional anisotropy, making it important to examine these com-
ponents separately (Acosta-Cabronero et al., 2010). DTI can be
used to characterize grey matter microstructure too (Bozzali et al.,
2002; McKinstry et al., 2002), with mean diffusivity a commonly
used metric (Benedetti et al., 2006). In fibre-rich structures such as
the thalamus and striatum, fractional anisotropy may also be a
useful indicator of pathological change (Ciccarelli et al., 2001;
Tovar-Moll et al., 2009; Bohanna et al., 2011). Many DTI studies
of sporadic Alzheimer’s disease have now been published, report-
ing decreased fractional anisotropy and increased mean diffusivity
in various tracts, most notably the cingulum, corpus callosum and
white matter of the parahippocampal gyrus (Chua et al., 2008;
Stebbins and Murphy, 2009). There has been just one previous
DTI study of presymptomatic familial Alzheimer’s disease, which
examined fractional anisotropy only and found it to be globally
reduced in the white matter of presymptomatic mutation carriers,
most strikingly in the fornix (Ringman et al., 2007).
We investigated a cohort of PSEN1 presymptomatic mutation car-
riers who were relatively close to their expected age at symptom
onset, together with groups of symptomatic mutation carriers and
control subjects. We used region of interest analyses to examine
volumetric and diffusivity differences in the subcortical structures
that are the main focus of this study, and altered diffusivity in
white matter tracts of interest. We also used automated whole
brain analysis techniques; voxel-based morphometry and tract-
based spatial statistics (TBSS), to provide whole-brain assessments
of group differences in volume and DTI indices, respectively.
Materials and methods
Subjects
Twenty PSEN1 muation carriers were included in this study, all of
whom had pathogenic mutations that have previously been reported
elsewhere. Ten of these were presymptomatic mutation carriers; three
M146I, two E184D and one each of M139V, Y115C, intron 4, L171P,
L262F. Ten were symptomatic mutation carriers; three intron 4, two
E280G and one each of Y115H, E120K, P264L, R269H and R278I. A
group of 20 healthy control subjects (including two gene-negative
siblings) was also studied. All subjects in the study underwent assess-
ment with the Mini-Mental State Examination. The PSEN1 mutation
carriers also underwent neurological examination and detailed neuro-
psychological assessment. The neuropsychological test battery com-
prised measures of general intellectual functioning (Wechsler
Abbreviated Scale of Intelligence), estimated premorbid IQ (National
Adult Reading Test); verbal and visual recognition memory
(Recognition Memory Test for words and faces); naming (Graded
Naming Test); calculation (Graded Difficulty Arithmetic Test); visuoper-
ceptual skills (object decision test from the Visual Object and Space
Perception battery); speed and executive function (Stroop Test). All
mutation carriers identified a close informant who was interviewed
separately to gain a collateral history; specific enquiry was made re-
garding cognitive symptoms in each domain, anxiety and depression.
Mutation carriers were defined as symptomatic if consistent symptoms
of cognitive decline were reported by the subject and/or their close
informant. If there was a discrepancy between the opinion of the
subject and their informant, the perspective of the informant was fa-
voured as insight may not always be preserved in familial Alzheimer’s
disease. Estimated time to onset was calculated for the presympto-
matic mutation carriers by subtracting the participant’s current age
from the age at which their parent first developed symptoms of pro-
gressive cognitive decline. The participants were recruited from an
ongoing longitudinal study of familial Alzheimer’s disease at the
Dementia Research Centre, University College London (UCL)
Institute of Neurology, which receives research referrals from across
the UK. Some of the subjects had participated in our previous imaging
studies of familial Alzheimer’s disease (Ridha et al., 2006; Knight et al.,
2011a, b) but the data used for this study have not been reported
elsewhere. All of the subjects in this study were aware of their muta-
tion status, having undergone clinical diagnostic or predictive genetic
testing at approved clinical centres separately to their involvement in
research. All subjects gave written informed consent according to the
Declaration of Helsinki and approval was received from the local ethics
committee. Consent was taken by a clinician experienced in the as-
sessment of patients with cognitive impairment and all subjects were
considered to have capacity to consent according to the Mental
Capacity Act of 2005. Subject demographics are detailed in Table 1.
Magnetic resonance image acquisition
All subjects were scanned on the same 3 T Siemens TIM Trio scanner
using a 32-channel phased array head-coil. A sagittal 3D MP-RAGE T1-
weighted volumetric MRI (echo time/repetition time/inversion
time = 2.9/2200/900 ms, dimensions of 256  256  208, voxel size
of 1.1  1.1  1.1 mm) and a coronal T2 FLAIR sequence (echo time/
repetition time/inversion time = 87/9000/2500 ms, voxel size of
0.9375  0.9375  5 mm) were acquired. Two 64-direction DTI se-
quences were acquired with a single shot, spin-echo echo planar
imaging (EPI) sequence (field of view 240 mm; matrix 96  96; yielding
an isotropic voxel size of 2.5  2.5  2.5 mm; 55 contiguous axial slices;
repetition time: 6800 ms; echo time: 91 ms; b-value: 1000 s/mm2), aug-
mented with parallel imaging acceleration (GRAPPA). Nine acquisitions
without diffusion weighting were acquired (b = 0 s/mm2). For all sub-
jects, volumetric T1, DTI and T2 FLAIR images were assessed visually in
all planes to ensure adequate coverage and to exclude significant motion,
artefacts or unexpected pathology.
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Grey matter region of interest
volumetric analysis
Region of interest segmentation in T1-weighted space was used to
investigate the volumes of the subcortical structures of interest in
this study; namely the thalamus, caudate, putamen and hippocampus.
The Multi-Atlas Propagation and Segmentation technique was used
(Keihaninejad et al., 2011), which was previously developed for hip-
pocampal segmentation and has been used in brain extraction (Leung
et al., 2010, 2011). In Multi-Atlas Propagation and Segmentation, all
of the atlases in a template library are first compared with the target
image. Our template library consisted of 30 subjects (median age of
31  8 years, 15 females) whose MRI scans had been manually seg-
mented into 83 anatomical structures (Hammers et al., 2003). Multiple
best-matched atlases were then selected, and the labels in the selected
atlases were propagated to the target image after non-linear image
registration. Label fusion was then applied to combine the labels from
different atlases to create a consensus segmentation in the target
image. We applied Multi-Atlas Propagation and Segmentation to
30 atlas images in a leave-one-out approach in order to determine
the number of best-matched atlases (7-9) and the optimal label
fusion technique [simultaneous truth and performance level estimation
(STAPLE)] (Warfield et al., 2004) required to produce accurate indi-
vidual regions of interest by comparing them to the manually deli-
neated regions. We used the optimized Multi-Atlas Propagation and
Segmentation technique to generate individual regions of interest for
each subject in our data set (Fig. 1). The anatomical validity of the
segmentations was confirmed by two consultant neuroradiologists.
Grey matter region of interest diffusion
tensor imaging analysis
All DTI were registered to the first b = 0 image using 12 degrees of free-
dom FLIRT (FMRIB Software Library) (Jenkinson et al., 2002) for motion
and eddy current correction and realigning diffusion-weighting direc-
tions appropriately. Tensor fitting was performed using Camino (Cook
et al., 2006). For each subject, the T1-weighted image was registered to
the first (b = 0) DTI image using a 12-parameter affine registration
Table 1 Subject demographics, neuropsychological and clinical data
Presymptomatic
mutation carriers
(4 males, 6 females)
Symptomatic
mutation carriers*
(6 males, 4 females)
Control subjects
(9 males,
11 females)
P-value
Age, years 37.8 (4.7) 49 (9.4) 44.3 (12.7) 0.27a (SMC versus control)
0.04a (PMC versus control)
50.01a (PMC versus SMC)
Years from estimated age at onset 5.6 (7) N/A N/A
Disease duration, years N/A 4.3 (1.7) N/A
MMSE/ 30 (range) 29 (28–30) 19 (13–24) 29.9 (29–30) 50.01b (SMC versus control)
0.02b (PMC versus control)
50.01b (PMC versus SMC)
Years of education 13 (2.5) 12 (1.7) N/A 0.20a
Neuropsychology
NART estimated IQ 100.2 (12.9) 100.1 (12.5) N/A 0.98a
WASI Verbal IQ 101.7 (18.0) 81.2 (17.5) N/A 0.02a
WASI Performance IQ 106.7 (17.1) 69.0 (15.0) N/A 50.01a
RMT words (/50) 45.9 (3.5) 30.0 (8.1) N/A 50.01c
RMT faces (/50) 42.6 (5.3) 32.4 (7.5) N/A 50.01c
Graded naming test (/30) 19.0 (5.0) 13.1 (7.8) N/A 0.5c
Graded difficulty arithmetic (/24) 12.9 (6.4) 2.4 (2.4) N/A 50.01c
Object decision (/20) 18.2 (2.1) 15.6 (3.2) N/A 0.06c
Stroop colour (s) 36.2 (14.8) 63.3 (18.3) N/A 50.0a
Stroop word (s) 23.1 (8.4) 49.1 (22.1) N/A 50.01a
Stroop ink colour (s) 58.7 (20.5) 124.4 (30.9) N/A 50.01a
CLINICAL**
Anxiety 10% 40% N/A
Depression 20% 60% N/A
Seizures 0% 0% N/A
Myoclonus 40% 60% N/A
Pyramidal signs 0% 60% N/A
Extrapyramidal signs 0% 20% N/A
Values are mean (SD); MMSE = Mini-Mental State Examination; RMT = Recognition Memory Test.
*n = 9 for all neuropsychological measures except Wechsler Abbreviated Scale of Intelligence Performance IQ (WASI PIQ; n = 10), National Adult Reading Test (NART;
n = 7) and Stroop colour ink interference (n = 5), with all reductions in n reflecting participants being untestable on specific tasks. Data for the complete cohort were
available for all other statistical tests.
**Percentage in group manifesting the clinical feature.
a Unpaired t-test, two-tailed test.
b Wilcoxon ranksum test.
c Linear regression with group and age as independent variables.
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algorithm (Ourselin et al., 2001). The regions of interest defined using
Multi-Atlas Propagation and Segmentation were transferred to the DTI
space using nearest-neighbour interpolation. The overall average frac-
tional anisotropy and mean diffusivity values were calculated by aver-
aging values for the entire individual region of interest.
White matter tract of interest diffusion
tensor imaging analysis
White matter tract of interest analysis was performed using DTI-TK to
create a study-specific template using iterative tensor-based registra-
tion, which takes into account local fibre orientation (Zhang et al.,
2006; Keihaninejad et al., 2012a). In particular, all linear and
non-linear registrations on the tensor images were performed using
DTI-TK, which has recently been shown to outperform the more con-
ventional tools (Wang et al., 2011). Fractional anisotropy, mean, axial
and radial diffusivity maps were created for the study-specific template
and registered images. The ICBM-DTI-81 white matter labels and
tracts atlas, developed by Johns Hopkins University was used to
locate the white matter tracts of interest (Mori et al., 2005). The
fractional anisotropy map of the Johns Hopkins University atlas was
linearly and non-linearly registered to the study-specific template frac-
tional anisotropy map (Ourselin et al., 2001; Modat et al., 2010). This
transformation was used to warp the labels from the white matter
atlas to the template fractional anisotropy image through nearest
neighbour interpolation. In this study, we focused on six white
matter tracts of interest: the genu, body, and splenium of the
corpus callosum, fornix and left and right cingulum (Fig. 1).
Statistical tests for non-voxelwise
analyses
Baseline characteristics and neuropsychological test results (which were
converted to z scores, based on published normative data) were com-
pared using t-tests for normally distributed variables and Wilcoxon
rank sum testing for the Mini-Mental State Examination. Linear regres-
sion was used to factor out age effects on neuropsychological tests
where no detailed age corrections were available (Recognition
Memory Test, Graded Naming Test, Graded Difficulty Arithmetic and
Object Decision). For the region of interest analyses, groups were
compared using separate linear regressions for each outcome measure,
in each region of interest. The region of interest volumetric analyses
were adjusted for age, gender and total intracranial volume. The
region of interest DTI analyses for grey and white matter were ad-
justed for age and gender. Total intracranial volume correction is not
required for DTI as it assesses microstructural properties that are not
expected to be associated with macroscopic head size. All results are
reported as statistically significant if P5 0.05.
Voxel-based morphometry analysis of
volumetric imaging
Voxel-based morphometry processing was carried out using SPM8
(Statistical Parametric Mapping, version 8; Wellcome Trust Centre
for Neuroimaging, London, UK). The T1-weighted scans were seg-
mented into grey and white matter using the new segment toolbox
Figure 1 Regions of interest. Grey matter regions of interest (top): segmentations of thalamus (blue), caudate (green), putamen (pink)
and hippocampus (purple) overlaid on the T1 image of a single subject. White matter tracts of interest (bottom): segmentations of the
fornix (pale blue), right cingulum (purple), left cingulum (green), genu (yellow), body (red) and splenium (dark blue) of the corpus
callosum, overlaid on the study-specific template.
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with default settings (Weiskopf et al., 2011). Segmentations were
produced with rigid alignment to standard space [Montreal
Neurological Institute (MNI) space] and resampled to 1.5 mm isotropic
voxels for use with DARTEL (Ashburner, 2007). DARTEL then itera-
tively registered the grey and white matter segments to an evolving
estimate of their group-wise average (Ashburner and Friston, 2009).
The native space tissue segments were then normalized to MNI space
using the DARTEL transformations, modulated to account for volume
changes. A smoothing kernel of 6 mm full-width at half-maximum was
applied. Total intracranial volume was calculated for each subject using
Jacobian integration of deformation fields created by the new segment
toolbox (Ridgway et al., 2011). Voxel-wise statistical analysis was per-
formed with non-parametric permutation-testing using the FMRIB
Software Library randomize program (as used for the TBSS statistical
analysis, described below). Grey and white matter images were mod-
elled separately in terms of group (control, presymptomatic, symptom-
atic), age, gender and total intracranial volume (all mean centred).
Statistical significance of differences between groups was assessed
using threshold-free cluster enhancement (Smith and Nichols, 2009),
controlling family-wise error (FWE). Results for symptomatic patients
are shown thresholded at FWE P5 0.05; presymptomatic differences
are shown at a less stringent level of FWE P5 0.1, with effect-maps
(difference between adjusted group means as a percentage of the
control mean) provided for a fuller characterization of the atrophy
pattern.
Voxel-wise diffusion tensor imaging
analysis using tract-based spatial
statistics
The DTI data were also analysed with TBSS to investigate whole-brain
white matter microstructural abnormalities (Smith et al., 2006). In this
study the modified TBSS protocol was used by incorporating a
group-wise atlas as the registration target; group-wise TBSS
(Keihaninejad et al., 2012b). In the group-wise TBSS pipeline, a
group-wise atlas is first created based on the subset subjects’ fractional
anisotropy images using the method described in Keihaninejad et al.
(2012b). The voxel-wise statistical analysis was performed by the FSL
randomize program (5000 random permutations) with correction for
multiple comparisons to control FWE (P5 0.05) using threshold-free
cluster enhancement. Age and gender were entered into the analysis
as covariates.
Results
The subjects’ demographic, neuropsychological and clinical data
are summarized in Table 1. The presymptomatic mutation carrier
(PMC) group was, as expected, younger than the symptomatic
mutation carrier (SMC) group and was on average 5.6 years
below the expected age at symptom onset. The mean age of
the control group (44.3 years) fell between that of the PMC
(37.8 years) and SMC groups (49.0 years) and age was used as
a covariate in all analyses, as was gender. There was no clinically
relevant difference in Mini-Mental State Examination score be-
tween the control subjects and presymptomatic mutation carriers;
symptomatic mutation carriers had significantly lower Mini-Mental
State Examination scores than both groups as expected.
The PMC and SMC groups were well matched for educational
level and estimated premorbid IQ. Figure 2 shows mean and
standard error z-scores for the PMC and SMC groups on neuro-
psychological tests. The PMC group showed no significant deficit
on any neuropsychological measure. The SMC group had signifi-
cantly poorer performance than the PMC group on all tests except
naming (Graded Naming Test) and object perception.
The clinical data showed that neuropsychiatric symptoms were
common in the SMC group; 40% had anxiety and 60% had de-
pression. In the PMC group, 10% had anxiety and 20% had de-
pression. The two presymptomatic mutation carriers with
symptoms of anxiety and/or depression were both within 2
years of their expected age at onset; both had a long history of
recurrent psychiatric symptoms since their teenage years and
required psychiatric review and medication changes at the time
of their current assessment. None of the subjects had seizures
but 60% of the symptomatic mutation carriers and 40% of the
presymptomatic mutation carriers had myoclonus on neurological
examination. Myoclonus was the only abnormal sign present on
examination of the presymptomatic mutation carriers but 20% of
the symptomatic mutation carriers had extrapyramidal signs and
Figure 2 Mean and standard error z-scores for presymptomatic and symptomatic mutation carriers on standard neuropsychological tests.
GDA = Graded Difficulty Arithmetic; GNT = Graded Naming Test; PIQ = performance IQ; RMT = Recognition Memory Test; VIQ = verbal IQ.
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60% had pyramidal signs, typically a symmetrical spastic increase
in lower limb tone with hyper-reflexia.
The grey matter region of interest volumetric analysis demon-
strated significant atrophy of the left thalamus in presymptomatic
mutation carriers compared with control subjects (P = 0.023), to-
gether with significant atrophy of both left caudate (P = 0.025)
and right caudate (P = 0.001). Refer to Table 2 for all the grey
matter region of interest volumetric and DTI results. No areas of
significant grey or white matter volume loss were seen in the PMC
group versus control subjects in the less sensitive voxel-based
morphometry analysis after correction for multiple comparisons
at the conventional level of FWE P50.05. However, atrophy in
the bilateral thalamic region was near significant [FWE P = 0.061,
at MNI coordinates of (4.5, 13.5, 12) mm]. Results thresholded
at FWE P50.1, together with an unthresholded effect map are
shown in Fig. 3. All of the grey matter regions of interest were
significantly atrophied in the SMC group compared with control
subjects. The voxel-based morphometry results for the SMC versus
control group comparison demonstrated grey matter volume loss
in bilateral hippocampus and posterior cortical areas but the most
significant volume loss was seen in the region of bilateral striatum
and thalamus. Extensive loss of white matter volume was also
observed in the symptomatic mutation carriers compared with
control subjects (Fig. 4).
In the presymptomatic group, no significant hippocampal atro-
phy was evident, although the right hippocampus did show sig-
nificantly decreased mean diffusivity (P = 0.046) in the grey matter
region of interest DTI analysis relative to control subjects.
Although not reaching significance, there was also a trend towards
decreased mean diffusivity in all the other subcortical structures in
presymptomatic mutation carriers. This contrasts with the findings
in the symptomatic mutation carriers, who demonstrated increased
mean diffusivity in all the subcortical grey matter structures as-
sessed; the pattern of change in diffusivity that is more typically
observed in neurodegenerative disease. In the presymptomatic
mutation carriers, fractional anisotropy was increased in the left
thalamus (P = 0.016), right thalamus (P = 0.036) and left caudate
(P = 0.004). Fractional anisotropy was also increased in symptom-
atic mutation carriers in left putamen (P = 0.032) and right puta-
men (P = 0.020), but did not differ significantly from control
subjects in the other grey matter structures assessed.
In the white matter tract of interest analysis, presymptomatic
mutation carriers demonstrated decreased mean diffusivity
(P = 0.043) and axial diffusivity (P = 0.011) in the right cingulum
only (Table 3). Significantly decreased fractional anisotropy with
increased mean, axial and radial diffusivity was seen in all the
white matter tracts of interest in the symptomatic mutation car-
riers. The TBSS analysis demonstrated widespread decreased frac-
tional anisotropy and increased mean, axial and radial diffusivity in
the white matter of symptomatic mutation carriers. As demon-
strated in Fig. 5, the fall in fractional anisotropy in the fornix
and cingulum of the SMC group appeared to be driven by an
increase in radial diffusivity; very little difference in axial diffusivity
was seen in these structures between the symptomatic mutation
carriers and control subjects. No significant differences in any of
the DTI indices were seen in the TBSS analysis for presymptomatic
mutation carriers versus control subjects.
As a supplementary analysis, region of interest measures for the
PMC versus SMC groups were compared. Significantly decreased
fractional anisotropy with increased mean, axial and radial diffu-
sivity was found in all white matter regions of interest in symp-
tomatic mutation carriers. All grey matter regions of interest
except from the caudates had significantly smaller volumes in
symptomatic mutation carriers compared with presymptomatic
mutation carriers. Whereas fractional anisotropy did not differ,
mean diffusivity was significantly increased in all grey matter re-
gions of interest of symptomatic mutation carriers except right
thalamus and left caudate, where the increase was of borderline
significance (P = 0.061 and P = 0.075, respectively).
Discussion
It has been established from Pittsburgh compound B-PET imaging
studies that the striatum and thalamus are affected early in the
presymptomatic stage of familial Alzheimer’s disease by amyloid
deposition (Klunk et al., 2007; Knight et al., 2011b). We demon-
strated atrophy of the caudate and thalamus in a cohort of pre-
symptomatic mutation carriers who were on average 5.6 years
prior to their expected age at onset. Half of these presymptomatic
mutation carriers had participated in a previous Pittsburgh com-
pound B-PET study, which found increased thalamic and striatal
amyloid deposition compared with control subjects (Knight et al.,
2011b). The findings of presymptomatic familial Alzheimer’s dis-
ease studies will clearly depend on how far from symptom onset
the individuals in the study are. A previous study examining the
caudate in presymptomatic familial Alzheimer’s disease interest-
ingly demonstrated an unexpected increase in the volume of the
caudate, precuneus and parietotemporal areas in presymptomatic
mutation carriers who were on average 9.9 years from expected
age at onset (Fortea et al., 2010). The authors of this paper
speculated that reactive neuronal hypertrophy and/or inflamma-
tory processes early in the presymptomatic stage may account for
an initial increase in the volume of these structures, which then
undergo progressive atrophy as the disease progresses. Although
their findings, like ours, need to be replicated in larger longitudinal
studies, it is quite possible that pathological processes early in the
presymptomatic stage cause dynamic changes in the volume of
affected structures, which alter in terms of the direction of change
as symptom onset is approached. Their DTI results, like ours,
showed a widespread increase in mean diffusivity in symptomatic
mutation carriers and a contrasting decrease in mean diffusivity in
the presymptomatic mutation carriers.
Increased mean diffusivity and decreased fractional anisotropy
are thought to reflect loss of integrity of cellular structures and are
commonly observed in neurodegenerative diseases, as was the
case with the symptomatic mutation carriers in our study. The
presymptomatic mutation carriers, on the other hand, showed sig-
nificantly decreased mean diffusivity in the right hippocampus and
a trend towards decreased mean diffusivity in the other subcortical
structures studied. Decreased mean diffusivity may reflect earlier
pathological changes in the pathway towards neurodegeneration,
such as microglial activation/accumulation and swelling of neurons
and glia. In a triple transgenic mouse model of Alzheimer’s disease
Thalamus and caudate in familial AD Brain 2013: Page 7 of 16 | 7
 at U
niversity College London on A
pril 8, 2013
http://brain.oxfordjournals.org/
D
ow
nloaded from
 
the appearance of neuritic plaques is associated with hippocampal
astrogliosis and microglial activation and is preceded by an in-
crease in the density of resting microglia (Olabarria et al., 2010;
Rodriguez et al., 2010). A DTI study of the APPsw transgenic
mouse found that the time of significant amyloid plaque accumu-
lation coincided with a fall in the magnitude of diffusion in
hippocampus and cerebral cortex (Sun et al., 2005). Microglial
activation PET studies have demonstrated increased thalamic bind-
ing following traumatic brain injury (Ramlackhansingh et al.,
2011) and middle cerebral artery infarction (Pappata et al.,
2000), with decreased thalamic mean diffusivity seen initially in
acute stroke (Herve et al., 2005), perhaps supporting the
Table 2 Mean  SD volumes and diffusivity indices in the grey matter regions of interest
Control subjects Presymptomatic mutation carriers Symptomatic mutation
carriers
Volume (mm3)
Right thalamus 7792  550 7676  747 6103  543
275 (152, 703) 1620 (1294, 1947)*
Left thalamus 7177  652 6962  604 5520  404
428 (64, 792)* 1533 (1216, 1849)*
Right caudate 4689  512 4273  553 3832  525
605 (293, 917)* 746 (438, 1053)*
Left caudate 4743  506 4376  610 3748  588
466 (63, 868)* 940 (537, 1343)*
Right putamen 5210  656 5234  695 4228  473
144 (250, 537) 920 (555, 1285)*
Left putamen 5035  680 4989  775 3847  655
194 (232, 620) 1142 (736, 1548)*
Right hippocampus 3131  304 3153  483 2295  477
1.76 (233, 230) 868 (632, 1103)*
Left hippocampus 3014  278 3118  423 2302  459
116 (345, 112) 769 (546, 991)*
Fractional anisotropy
Right thalamus 0.352  0.017 0.367  0.019 0.346  0.031
0.017 (0.032, 0.001)* 0.006 (0.014, 0.025)
Left thalamus 0.332  0.013 0.343  0.008 0.327  0.031
0.013 (0.023, 0.003)* 0.007 (0.011, 0.025)
Right caudate 0.229  0.024 0.239  0.030 0.243  0.034
0.017 (0.038, 0.004) 0.013 (0.037, 0.010)
Left caudate 0.226  0.017 0.248  0.026 0.236  0.027
0.025 (0.041, 0.009)* 0.011 (0.029, 0.008)
Right putamen 0.222  0.016 0.227  0.013 0.242  0.020
0.009 (0.021, 0.003) 0.017 (0.031, 0.003)*
Left putamen 0.212  0.011 0.214  0.010 0.228  0.021
0.005 (0.013, 0.003) 0.014 (0.027, 0.001)*
Right hippocampus 0.184  0.016 0.193  0.022 0.176  0.032
0.006 (0.0214, 0.009) 0.004 (0.014, 0.023)
Left hippocampus 0.178  0.019 0.192  0.020 0.167  0.033
0.012 (0.029, 0.005) 0.007 (0.013, 0.028)
Mean diffusivity
Right thalamus 0.824  0.030 0.794  0.043 0.912  0.089
0.022 (0.006, 0.049) 0.075 (0.119, 0.032)*
Left thalamus 0.838  0.029 0.815  0.037 0.915  0.069
0.016 (0.010, 0.042) 0.070 (0.108, 0.032)*
Right caudate 0.956  0.071 0.949  0.068 1.075  0.111
0.005 (0.057, 0.066) 0.113 (0.185, 0.040)*
Left caudate 0.993  0.081 0.955  0.066 1.058  0.072
0.013 (0.045, 0.071) 0.052 (0.112, 0.008)
Right putamen 0.761  0.026 0.740  0.028 0.840  0.060
0.016 (0.006,0.038) 0.075 (0.108,0.041)*
Left putamen 0.773  0.040 0.752  0.021 0.838  0.061
0.012 (0.016, 0.039) 0.061 (0.010,0.022)*
Right hippocampus 0.958  0.033 0.907  0.073 1.094  0.073
0.044 (0.002, 0.087)* 0.139 (0.181,0.096)*
Left hippocampus 0.952  0.052 0.921  0.053 1.113  0.096
0.027 (0.017, 0.072) 0.163 (0.221,0.104)*
The differences in adjusted means between the mutation carriers and control group (95% confidence interval) are shown in italics. Significant results
at P50.05 are indicated by an asterisk.
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hypothesis that gliosis accounts for the low mean diffusivity
observed in presymptomatic mutation carriers. Microglia undergo
persistent activation at sites of white matter damage (Wilson
et al., 2004), which may explain why they are observed in densely
connected subcortical structures. In axonal injury, APP is upregu-
lated in white matter at the site of trauma but is later seen in the
dorsal thalamus (Spain et al., 2010), where neuronal atrophy, but
not cell death, has been observed (Lifshitz et al., 2007).
The PMC group in our study showed increased fractional an-
isotropy in bilateral thalamus and left caudate and, in the SMC
group, increased putamen fractional anisotropy was seen bilat-
erally. Fractional anisotropy reflects the degree of directionality
of diffusion of water molecules within a structure; it is therefore
highest in white matter tracts, lower in grey matter and lowest in
CSF. The anisotropy of the thalamus and striatum is probably due
to their compartmentalized cytoarchitectural organization, to-
gether with the large number of white matter fibres passing
through them (Wiegell et al., 2000). Similar to our findings, a
pattern of increased fractional anisotropy in the thalamus and
basal ganglia has been observed in patients with multiple sclerosis
(Ciccarelli et al., 2001; Tovar-Moll et al., 2009). It has been sug-
gested that this may be due to the selective degeneration of white
matter fibres connecting these subcortical structures with cortical
areas combined with the relative preservation of anisotropic intrin-
sic connections between the structures themselves. This may result
in an overall increase in the fractional anisotropy of the subcortical
structures. By the same presumed mechanism, increased fractional
anisotropy was found in a group of patients with mild cognitive
impairment compared with control subjects in the centrum semi-
ovale, due to degeneration of association fibres of the superior
longitudinal fasciculus where they cross with intact motor projec-
tion fibres (Douaud et al., 2011).
Decreased mean diffusivity and axial diffusivity were observed
in the right cingulum of the PMC group, whereas increased mean,
axial and radial diffusivity occurred in all white matter regions
of interest of the symptomatic mutation carriers. This pattern of
events also conforms with the findings of pathological studies of
axonal damage. Axonal injury initially causes swelling, beading and
fragmentation of axons with an associated fall in axial diffusivity,
probably because intracellular diffusion is hindered by the
damaged membranes whilst axonal swelling and beading
impedes diffusion in both the intracellular and extracellular space
(Budde and Frank, 2010). Following subsequent clearance of
membrane fragments, the decreased axonal density permits
increased parallel diffusion in the extra-axonal space and therefore
increased axial diffusivity, together with increased radial diffusivity
Figure 3 Voxel-based morphometry results showing (top left) areas of grey matter reduction in presymptomatic mutation carriers
compared with control subjects after correction for multiple comparisons at FWE50.1 and the effect-map for the PMC versus control
group comparison. In the effect-map, regions showing reduced grey matter in the PMC group are shown in red and in control subjects in
blue. Differences between the two adjusted group-means are overlaid on a mean study-specific template. Images shown in radiological
convention (right on left).
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secondary to myelin degradation (Song et al., 2003; Concha et al.,
2006). In the APPsw transgenic mouse DTI study, decreased axial
diffusivity was seen diffusely in the white matter from the time of
amyloid plaque accumulation, with increased radial diffusivity
occurring in the corpus callosum at a later stage (Sun et al.,
2005). Although each variable was examined separately, the
TBSS results in our study suggest a more prominent increase in
radial than axial diffusivity in symptomatic mutation carriers com-
pared with control subjects, particularly in the fornix and cingu-
lum, which may be because of this gradual transition of axial
diffusivity from decreased to increased with advancing axonal de-
generation. Other studies of early Alzheimer’s disease have also
found more prominent increases in radial than axial diffusivity,
with axial diffusivity decreased in some tracts (Huang et al.,
2007).
Several pathogenic pathways are likely to contribute to the
axonal degeneration witnessed in Alzheimer’s disease, including
defects in fast axonal transport resulting from enhanced
production of amyloid-b (Kanaan et al., 2013). Neurons, having
longer dendrites and axons than any other cell type, are particu-
larly vulnerable to impaired fast axonal transport, which may be
why familial Alzheimer’s disease-causing mutations selectively
affect neurons despite being ubiquitously expressed in cells
throughout the body. It may also explain why short interneurons
tend to be relatively spared in Alzheimer’s disease compared with
long projection neurons (Mattson and Magnus, 2006), an obser-
vation that could well underlie our finding of increased fractional
anisotropy in the thalamus and caudate in presymptomatic familial
Alzheimer’s disease. The cingulum bundle, where we observed
presymptomatic diffusivity changes, is composed of particularly
long-coursing white matter tracts, arising from the thalamus, cin-
gulate gyrus and cortical association areas. It is the major route for
projections from the anterior thalamus to cingulate cortex, hippo-
campus and retrohippocampal regions; a network that is thought
to play a key role in memory and spatial orientation (Neave et al.,
1997). These cognitive functions are often impaired early in
Figure 4 Voxel-based morphometry results showing (top) grey matter reduction and (bottom) white matter reduction in symptomatic
mutation carriers compared with control subjects. Results are shown overlaid on a mean study-specific template and are FWE-corrected
for multiple comparisons. Images shown in radiological convention (right on left).
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Alzheimer’s disease, perhaps because neurons lose their functional
connections with increasing axonal damage. Eventually, once the
damage has reached a stage where trophic signalling is no longer
available, overt neurodegeneration may occur.
A number of strands of evidence suggest that a network of
limbic neurons undergoes selective degeneration in early
Alzheimer’s disease, including PET findings of hypometabolism in
the thalamus, mamillary bodies, hippocampus and posterior
Table 3 Mean  SD diffusivity indices in the white matter tracts of interest
Control Presymptomatic Symptomatic
Fractional anistropy
Genu of corpus callosum 0.610  0.026 0.621  0.040 0.570  0.010
0.010 (0.017, 0.037) 0.040 (0.059, 0.021)*
Body of corpus callosum 0.612  0.026 0.613  0.045 0.559  0.012
0.000 (0.029, 0.028) 0.054 (0.074,0.034)*
Splenium of corpus callosum 0.684  0.020 0.691  0.028 0.639  0.020
0.005 (0.015, 0.025) 0.045 (0.063,0.027)*
Fornix 0.426  0.044 0.458  0.094 0.332  0.046
0.017 (0.036, 0.069) 0.092 (0.130,0.054)*
Right cingulum 0.481  0.033 0.503  0.059 0.402  0.019
0.018 (0.018, 0.054) 0.078 (0.102, 0.054)*
Left cingulum 0.457  0.035 0.467  0.050 0.385  0.018
0.011 (0.023, 0.044) 0.073 (0.098,0.047)*
Mean diffusivity
Genu of corpus callosum 0.849  0.043 0.835  0.057 0.942  0.026
0.010 (0.031, 0.052) 0.090 (0.058, 0.122)*
Body of corpus callosum 0.858  0.039 0.855  0.052 0.966  0.041
0.000(0.038, 0.037) 0.105 (0.071, 0.139)*
Splenium of corpus callosum 0.855  0.040 0.847  0.068 0.974  0.068
0.002 (0.042, 0.046) 0.117 (0.073, 0.160)*
Fornix 1.718  0.199 1.642  0.388 2.107  0.147
0.007 (0.214, 0.229) .369 (0.215, 0.523)*
Right cingulum 0.821  0.043 0.776  0.047 0.980  0.049
0.040 (0.001, 0.078)* 0.157 (0.119, 0.196)*
Left cingulum 0.776  0.050 0.752  0.062 0.911  0.040
0.019 (0.028, 0.066) 0.132 (0.092, 0.172)*
Axial diffusivity
Genu of corpus callosum 1.543  0.038 1.528  0.041 1.636  0.031
0.010 (0.023, 0.044) 0.088 (0.059, 0.118)*
Body of corpus callosum 1.569  0.040 1.562  0.021 1.661  0.041
0.003 (0.027, 0.033) 0.087 (0.054, 0.120)*
Splenium of corpus callosum 1.662  0.043 1.653  0.075 1.795  0.078
0.004 (0.044, 0.052) 0.130 (0.082, 0.178)*
Fornix 2.536  0.188 2.454  0.335 2.832  0.136
0.021 (0.177, 0.219) 0.279 (0.134, 0.424*)
Right cingulum 1.291  0.046 1.248  0.020 1.394  0.054
0.042 (0.010, 0.074)* 0.102 (0.062, 0.142)*
Left cingulum 1.188  0.049 1.161  0.039 1.281  0.043
0.018 (0.021, 0.057) 0.088 (0.049, 0.128)*
Radial diffusivity
Genu of corpus callosum 0.503  0.048 0.488  0.068 0.595  0.026
0.010 (0.037, 0.057) 0.090 (0.055, 0.125)*
Body of corpus callosum 0.503  0.043 0.502  0.069 0.618  0.042
0.002 (0.047, 0.043) 0.114 (0.078, 0.151)*
Splenium of corpus callosum 0.451  0.041 0.444  0.066 0.563  0.064
0.001 (0.042, 0.044) 0.110 (0.068, 0.152)*
Fornix 1.310  0.206 1.236  0.416 1.744  0.155
0.001 (0.234, 0.235) 0.415 (0.255, 0.575)*
Right cingulum 0.585  0.050 0.540  0.073 0.772  0.048
0.039 (0.012, 0.089) 0.185 (0.143, 0.227)*
Left cingulum 0.569  0.057 0.547  0.079 0.725  0.043
0.019 (0.036, 0.075) 0.154 (0.109, 0.198)*
The differences in adjusted means between the mutation carriers and control group (95% confidence interval) are shown in italics. Significant results at P5 0.05 are
indicated by an asterisk.
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cingulate (Nestor et al., 2003). Along with the cingulum findings,
our observation of presymptomatic thalamic atrophy and increased
thalamic fractional anisotropy in familial Alzheimer’s disease adds
further support to this notion. The few pathological studies of
thalamic involvement in Alzheimer’s disease have demonstrated
extracellular amyloid deposits in almost all thalamic nuclei (Braak
and Braak, 1991) and significant thalamic atrophy, thought largely
to be due to loss of axons, dendrites and synaptic structures or
glial cell changes (Xuereb et al., 1991).
The striatum of patients with Alzheimer’s disease at
post-mortem has also been found to contain abundant amyloid
deposits with loss of large cholinergic neurons (Oyanagi et al.,
1987; Braak and Braak, 1990), which potentially underlies our
findings of striatal atrophy in familial Alzheimer’s disease. The ma-
jority of striatal nerve cells appear to resist the development of
neuritic change (Braak and Braak, 1990) despite the presence of
abundant amyloid, which is intriguing given that striatal involve-
ment on Pittsburgh compound B-PET scans is evident over a
decade before symptom onset in familial Alzheimer’s disease.
One possible hypothesis relates to differences in mechanisms of
calcium homeostasis in different neuronal populations. It has been
found that presenilins act as calcium leak channels in the endo-
plasmic reticulum of hippocampal neurons and many PSEN1 mu-
tations impair this leak function, resulting in endoplasmic reticulum
calcium overload and supranormal calcium release. In medium
spiny striatal neurons (the major neuronal cell type in the stri-
atum), the endoplasmic reticulum is much less leaky for calcium
and presenilins show less involvement in calcium homeostasis
(Nelson et al., 2010).
The idea that widespread white matter degeneration occurs in
familial Alzheimer’s disease is supported by the imaging findings in
our SMC cohort. Volume loss of the white matter appeared to be
more widespread than that of the grey matter in the voxel-based
morphometry analysis, and the TBSS results showed very diffuse
microstructural white matter abnormalities in the SMC cohort. A
variety of PSEN1 mutations are known to be associated with
Figure 5 TBSS results demonstrating areas of significantly decreased fractional anisotropy and significantly increased axial, radial and
mean diffusivity in symptomatic mutation carriers compared with control subjects. Results are FWE-corrected for multiple comparisons
using threshold-free cluster enhancement.
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spastic paraparesis and some individuals with the phenotype have
white matter hyperintensities visible on brain MRI (O’Riordan
et al., 2002; Ryan and Rossor, 2010). It would not, therefore,
be surprising if microstructural damage to the white matter gave
rise to more subtle pyramidal signs and our observation that 60%
of the symptomatic mutation carriers had lower limb spasticity and
hyper-reflexia may well relate to this white matter pathology. It is
not clear whether there are clinical correlates of the presympto-
matic thalamic and caudate changes we observed. Although extra-
pyramidal signs, often associated with striatal pathology, were
seen in 20% of the symptomatic mutation carriers they were
not seen presymptomatically. Presymptomatic myoclonus was
observed, as has been detected in previous studies (Godbolt
et al., 2004). The origin of this myoclonus is unknown but it is
possible that thalamocortical networks are implicated, as they are
in other conditions such as juvenile myoclonic epilepsy
(Gerschlager and Brown, 2009).
Neuropsychologically, the SMC cohort showed deficits in wide-
spread domains at the time they were studied, with verbal recog-
nition memory worst affected and perhaps some relative
preservation of naming and object perception, as has been
observed previously (Warrington et al., 2001; Godbolt et al.,
2004). No significant neuropsychological deficits were observed
in the PMC group, although 20% of these subjects and 60% of
the symptomatic mutation carriers had symptoms of depression
and/or anxiety. Anxiety and depression are relatively common in
both sporadic and familial Alzheimer’s disease and it is under-
standable that these symptoms may occur in presymptomatic mu-
tation carriers who are aware of their mutation status and
approaching the age at which they saw their parent develop
symptoms. However, it is worth noting that limbic circuits are
well known to be involved in emotional expression and lesions
to anterior thalamic nuclei have been found to cause a variety
of neuropsychiatric symptoms including sadness, agitation and
flattened affect, in addition to amnesia (Schmahmann, 2003).
Disentangling whether presymptomatic psychiatric symptoms are
related more to psychological factors or disease effects will require
longitudinal study of large cohorts of ‘at risk’ individuals, compris-
ing both mutation-positive and -negative individuals, who are un-
aware of their mutation status but exposed to the same anxieties
about the possibility of developing symptoms. Collaborative stu-
dies such as DIAN will be ideally placed to address these issues
and ascertain whether our findings are reproducible in larger
familial Alzheimer’s disease cohorts.
Our study had several limitations. Subject numbers were rela-
tively small, which limits power and may have accounted for the
fact that reduced thalamic volume and increased caudate frac-
tional anisotropy only reached statistical significance on the left
in the PMC region of interest analysis. Larger cohorts will be
required to investigate whether the onset of subcortical imaging
changes is indeed asymmetrical. The optimization of methods for
processing and analysing DTI data is an area of active research.
One potential issue with DTI is its sensitivity to susceptibility arte-
facts arising from neighbouring tissues having very different para-
magnetic properties, which can lead to distortions of echo planar
imaging and misregistration. The lack of echo planar imaging dis-
tortion correction in our study should be considered a minor
limitation, however the deep grey matter structures of interest in
this study do not tend to be severely affected by such artefacts
and a gold standard solution to the problem has not yet been
established (Gholipour et al., 2011). We used mean fractional an-
isotropy to investigate the regions of interest, which is common
practice in the literature, but is nevertheless an aspect that could
be improved in future work. Regional analysis (e.g. of thalamus)
cannot easily address subregional variation in the structure of
interest. Inspection of the grey matter region of interest histo-
grams indicates a degree of non-normality (distributions are
slightly skewed and heavier tailed to the right), which might mo-
tivate consideration of robust statistics, such as trimmed-mean or
an m-estimator (Hampel et al., 1986). Secondly, and more funda-
mentally, the nature of fractional anisotropy as a ratio suggests
that the use of an arithmetic mean (or robust version thereof)
might not be optimal as a measure of central tendency. For ex-
ample, a geometric mean (corresponding to a logarithmic distance
metric) is more appropriate for strictly positive but otherwise un-
bounded quantities. However, fractional anisotropy is bounded
between 0 and 1, and the optimal metric and mean are unclear.
More radically, it has been suggested that fractional anisotropy
should be replaced with a different measure of anisotropy
known as the geodesic anisotropy (Batchelor et al., 2005),
which would have a stronger theoretical basis than the combin-
ation of fractional anisotropy with robust non-arithmetic averages,
but requires further empirical evaluation.
In summary, we demonstrated presymptomatic thalamic and
caudate volume loss and increased fractional anisotropy, with
altered diffusivity in the right hippocampus and cingulum, in
PSEN1 mutation carriers who were 5.6 years from expected
age at onset. We propose that axonal degeneration is an early
event in familial Alzheimer’s disease pathogenesis and that amyl-
oid accumulation, atrophy and diffusivity changes are seen early
on in the thalamus and striatum due to the large number of white
matter tracts that these structures are connected with.
Involvement of a subcortical structure like the thalamus, which
forms a key node in a vulnerable neuronal network, could potenti-
ate the propagation of pathology through that network. The most
striking degeneration may then be observed in connected neuronal
populations, such as those of the hippocampus. How generalizable
our findings are to sporadic Alzheimer’s disease is an important
question. There is some evidence of early white matter tract de-
generation in sporadic Alzheimer’s disease from DTI studies of
mild cognitive impairment (Chua et al., 2008; Stebbins and
Murphy, 2009) and thalamic atrophy has also been demonstrated
in mild cognitive impairment (Pedro et al., 2012). In healthy con-
trol subjects at increased risk of sporadic Alzheimer’s disease due
to possession of an apolipoprotein E4 allele, decreased fractional
anisotropy has been found in several white matter tracts including
the cingulum (Smith et al., 2010) and volume loss of the hippo-
campus, but not thalamus or striatum, has been observed
(O’Dwyer et al., 2012). The same neuronal network appears to
disintegrate in both sporadic and familial Alzheimer’s disease but it
may be that different nodes of this circuit are particularly vulner-
able to different risk factors for the disease. The development of
more sensitive diffusion imaging techniques such as high-angular-
resolution diffusion imaging (HARDI) (Haroon et al., 2011) and
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neurite orientation dispersion and density imaging (NODDI)
(Zhang et al., 2012), and their application to the longitudinal
study of individuals at risk of both familial and sporadic
Alzheimer’s disease, may allow us to further investigate just how
early microstructural abnormalities become evident and when is
the optimal time for therapeutic intervention.
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